G. Favre

  Cancer cell signaling and therapeutics

 

 

 

 

 

Our research project at a glance

 

Cancer cells have deregulated signaling pathways that are involved in cell proliferation, survival, and tumor progression. Our general aim is to understand the molecular pathway abnormalities in cancer cells and translate our findings to the development of new therapeutic strategies in the clinic, in particular in lung cancers and melanoma.

 

Objectives

 

Our general aim is to understand molecular pathway abnormalities in cancer cells and to translate these laboratory results into the development of new therapeutic strategies.

We focus first on the receptor tyrosine kinase (RTK)/RAS/MAPK and RHOGTPase pathways to understand their connections with the control of cell proliferation, survival and tumor progression, and to design new therapeutic strategies.

Second, we study the signaling and repair mechanisms of DNA double-strand breaks (DSB) produced in transcribed regions, their cross-talk with oncogenic signaling, to understand their role in oncogenesis and resistance to targeted therapies.

Team strengths in the leading-edge biotechnologies of GFP-based protein/protein interaction and nanobody-based biosensors contribute to the discovery of new biological and clinical findings. Expertise in signal transduction and DNA damage response pathway has contributed directly and indirectly to new concepts in the resistance to targeted therapies and new target discovery.

In close collaboration with clinical departments, we develop translational and clinical research in lung cancers and melanomas.

 

Key words

 

  • Oncogenic signaling
  • RTK/RAS/MAPK and RHOGTPase pathways
  • Cell stress and double-strand break signaling
  • Biotechnology
  • Nanobodies
  • Split GFP
  • Lung cancers
  • Melanoma
  • Translational research
  • Biomarkers
  • Clinical trials

 

Selected publications


2017

Calvayrac, O; Mazieres, J; Figarol, S; Marty-Detraves, C; Raymond-Letron, I; Bousquet, E; Farella, M; Clermont-Taranchon, E; Milia, J; Rouquette, I; Guibert, N; Lusque, A; Cadranel, J; Mathiot, N; Savina, A; Pradines, A; Favre, G

The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism Journal Article

EMBO Mol Med, 9 (2), pp. 238-250, 2017, ISSN: 1757-4684 (Electronic) 1757-4676 (Linking).

Links | BibTeX

2016

Bousquet, E; Calvayrac, O; Mazieres, J; Lajoie-Mazenc, I; Boubekeur, N; Favre, G; Pradines, A

RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition Journal Article

Oncogene, 35 (14), pp. 1760-9, 2016, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).

Links | BibTeX

Cristini, A; Park, J H; Capranico, G; Legube, G; Favre, G; Sordet, O

DNA-PK triggers histone ubiquitination and signaling in response to DNA double-strand breaks produced during the repair of transcription-blocking topoisomerase I lesions Journal Article

Nucleic Acids Res, 44 (3), pp. 1161-78, 2016, ISSN: 1362-4962 (Electronic) 0305-1048 (Linking).

Links | BibTeX

Guibert, N; Pradines, A; Casanova, A; Farella, M; Keller, L; Soria, J C; Favre, G; Mazieres, J

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Journal Article

J Thorac Oncol, 11 (9), pp. e109-12, 2016, ISSN: 1556-1380 (Electronic) 1556-0864 (Linking).

Links | BibTeX

Moutel, S; Bery, N; Bernard, V; Keller, L; Lemesre, E; de Marco, A; Ligat, L; Rain, J C; Favre, G; Olichon, A; Perez, F

NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies Journal Article

Elife, 5 , 2016, ISSN: 2050-084X (Electronic) 2050-084X (Linking).

Links | BibTeX

Planchard, D; Kim, T M; Mazieres, J; Quoix, E; Riely, G; Barlesi, F; Souquet, P J; Smit, E F; Groen, H J; Kelly, R J; Cho, B C; Socinski, M A; Pandite, L; Nase, C; Ma, B; D'Amelio A., Jr. ; Mookerjee, B; Curtis C. M., Jr. ; Johnson, B E

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial Journal Article

Lancet Oncol, 17 (5), pp. 642-50, 2016, ISSN: 1474-5488 (Electronic) 1470-2045 (Linking).

Links | BibTeX

2015

Delmas, A; Cherier, J; Pohorecka, M; Medale-Giamarchi, C; Meyer, N; Casanova, A; Sordet, O; Lamant, L; Savina, A; Pradines, A; Favre, G

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors Journal Article

Oncotarget, 6 (17), pp. 15250-64, 2015, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).

Links | BibTeX

2014

Mamouni, K; Cristini, A; Guirouilh-Barbat, J; Monferran, S; Lemarie, A; Faye, J C; Lopez, B S; Favre, G; Sordet, O

RhoB promotes gammaH2AX dephosphorylation and DNA double-strand break repair Journal Article

Mol Cell Biol, 34 (16), pp. 3144-55, 2014, ISSN: 1098-5549 (Electronic) 0270-7306 (Linking).

Links | BibTeX

2013

Cabantous, S; Nguyen, H B; Pedelacq, J D; Koraichi, F; Chaudhary, A; Ganguly, K; Lockard, M A; Favre, G; Terwilliger, T C; Waldo, G S

A new protein-protein interaction sensor based on tripartite split-GFP association Journal Article

Sci Rep, 3 , pp. 2854, 2013, ISSN: 2045-2322 (Electronic) 2045-2322 (Linking).

Links | BibTeX

Mazieres, J; Peters, S; Lepage, B; Cortot, A B; Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Mansuet-Lupo, A; Urban, T; Moro-Sibilot, D; Dansin, E; Chouaid, C; Wislez, M; Diebold, J; Felip, E; Rouquette, I; Milia, J D; Gautschi, O

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives Journal Article

J Clin Oncol, 31 (16), pp. 1997-2003, 2013, ISSN: 1527-7755 (Electronic) 0732-183X (Linking).

Links | BibTeX